1-4 of 4
Gavin MacBeath
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract LB-C25: Inhibition of ERBB3 with MM-121, IGF1-R with MM-141 or Met with MM-131 increases the activity of EGFR inhibitor MM-151 in colorectal cancer models expressing multiple resistance ligands

Free
Marisa J. Wainszelbaum, Jessica Fessler, Johanna Lahdenranta, Olga Burenkova, Nat Gerami-Moayed, Yasmin Hashambhoy-Ramsay, Victoria Rimkunas, Gavin MacBeath
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): LB-C25.
https://doi.org/10.1158/1535-7163.TARG-15-LB-C25
Published: 01 December 2015
View article titled, Abstract LB-C25: Inhibition of ERBB3 with MM-121, IGF1-R with MM-141 or Met with MM-131 increases the activity of EGFR inhibitor MM-151 in colorectal cancer models expressing multiple resistance ligands
Journal Articles

Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor–Positive Breast Cancer Model

Free
Michael D. Curley, Gauri J. Sabnis, Lucia Wille, Bambang S. Adiwijaya, Gabriela Garcia, Victor Moyo, Armina A. Kazi, Angela Brodie, Gavin MacBeath
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (11): 2642–2652.
https://doi.org/10.1158/1535-7163.MCT-15-0169
Published: 03 November 2015
View article titled, Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor–Positive Breast Cancer Model
Open the PDF for Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor–Positive Breast Cancer Model in another window
Includes: Supplementary data
Journal Articles

Heregulin–ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells

Free
Defne Yarar, Johanna Lahdenranta, William Kubasek, Ulrik B. Nielsen, Gavin MacBeath
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (9): 2072–2080.
https://doi.org/10.1158/1535-7163.MCT-15-0075
Published: 02 September 2015
View article titled, Heregulin–ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells
Open the PDF for Heregulin–ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells in another window
Includes: Supplementary data
Journal Articles

Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma

Free
Ning Jiang, Dongsheng Wang, Zhongliang Hu, Hyung Ju C. Shin, Guoqing Qian, Mohammad Aminur Rahman, Hongzheng Zhang, A.R.M. Ruhul Amin, Sreenivas Nannapaneni, Xiaojing Wang, Zhengjia Chen, Gabriela Garcia, Gavin MacBeath, Dong M. Shin, Fadlo R. Khuri, Jun Ma, Zhuo G. Chen, Nabil F. Saba
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2014) 13 (7): 1826–1836.
https://doi.org/10.1158/1535-7163.MCT-13-1093
Published: 06 July 2014
View article titled, Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma
Open the PDF for Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma in another window
Includes: Supplementary data